葛兰素史克Glaxosmithkline plc (GSK) 2015年年度报告「LSE」.pdf

1、Annual Report 20152015 saw substantial progress to accelerate new product sales growth and strengthen our Pharmaceuticals,Vaccines and Consumer Healthcare businessesB GSK Annual Report 2015Strategic reportGovernance&remunerationFinancial statementsInvestor information“In 2015,we made substantial pro

2、gress to accelerate new product sales growth,integrate new businesses in Vaccines and Consumer Healthcare and restructure our global Pharmaceuticals business.This progress means the Group is well positioned to return to core earnings growth in 2016.”Sir Andrew Witty,Chief Executive OfficerOverview o

3、f 2015 Performance summaryFront cover storyInnovation is at the heart of all we do Katherine,pictured left,is one of a team of scientists continuing to develop Nucala after almost 20 years of focused R&D,including nine distinct patient studies.Nucala is a monoclonal antibody that stops IL-5 from bin

4、ding to its receptor on the surface of eosinophils.In people with asthma,eosinophils a type of white blood cell cause inflammation in the lungs,making it difficult to breathe and increasing the risk of asthma attacks.The 2015 European and US regulatory approvals of Nucala the first-in-class approved

5、 targeted biologic therapy for people with eosinophilic-driven severe asthma consolidates GSKs leading global position in respiratory medicine.Katherine,GSK senior scientist,Stevenage,UK23.9bnGroup turnover(up 6%CER/up 1%CER pro-forma)a10.3bnTotal operating profit(up 100%CER)a 5.7bnCore operating pr

6、ofit(down 9%CER/down 3%CER pro-forma)a3.9bnCash dividends paid in 20152.0bnNew product salesb(up 100%)174.3pTotal earnings per share(up 100%,primarily reflecting impact of transaction gains)75.7pCore earnings per share(down 15%CER,primarily reflecting short-term dilution of the Novartis transaction)